Direct analytical sample quality assessment for biomarker investigation: Qualifying cerebrospinal fluid samples

Proteomics

Volumn 14, Issue 17-18, 2014, Pages 1954-1962

  Greco, Viviana ^a,b   Pieragostino, Damiana ^c,d   Piras, Cristian ^e   Aebersold, Ruedi ^f,g   Wiltfang, Jens ^h   Caltagirone, Carlo ^b   Bernardini, Sergio ^a   Urbani, Andrea ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d Center of Excellence on Aging (CeSI)   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f ETH ZURICH   (Switzerland)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Biomarkers; Biomedicine; Cerebrospinal fluid; MALDI TOF MS; Neurodegenerative diseases; Sample quality control

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CYSTEINE; HEMOGLOBIN; HEMOGLOBIN ALPHA CHAIN;

ANALYTICAL ERROR; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTAMINATION; FREEZE THAWING; HUMAN; LUMBAR PUNCTURE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; QUALITY CONTROL; STORAGE; CLINICAL CHEMISTRY; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; NEURODEGENERATIVE DISEASES; STANDARDS;

BIOLOGICAL MARKERS; CLINICAL CHEMISTRY TESTS; HUMANS; NEURODEGENERATIVE DISEASES; QUALITY CONTROL; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84908626634     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300565     Document Type: Article

References (43)

1. Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C. et al., CSF biomarker variability in the Alzheimer's association quality control program. Alzheimer's Dement. 2013, 9, 251-261.
2. Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 131-144.
3. Häggmark, A., Byström, S., Ayoglu, B., Qundos, U. et al., Antibody-based profiling of cerebrospinal fluid within multiple sclerosis. Proteomics 2013, 13, 2256-2267.
4. Aebersold, R., Bader, G. D., Edwards, A. M., Van Eyk, J. E. et al., The biology/disease-driven human proteome project (B/D-HPP): enabling protein research for the life sciences community. J. Proteome Res. 2012, 12, 23-27.
5. Betsou, F., Gunter, E., Clements, J., DeSouza, Y. et al., Identification of evidence-based biospecimen quality-control tools: a report of the international society for biological and environmental repositories (ISBER) biospecimen science working group. J. Mol. Diagn. 2012, 15, 3-16.
6. The Lancet, N., Joining forces to fight neurodegenerative diseases. Lancet Neurol. 2013, 12, 119.
7. Teunissen, C. E., Tumani, H., Bennett, J. L., Berven, F. S. et al., Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult. Scler. Int. 2011, 2011, 1-9.
8. Simonsen, A. H., Bahl, J., Danborg, P. B., Lindstrom, V. et al., Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J. Neurosc. Methods 2013, 215, 234- 240.
9. Poulsen, K., Bahl, J., Tanassi, J. T., Simonsen, A. H., Heegaard, N. H., Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 2012, 56, 284-292.
10. Hubel, A., Aksan, A., Skubitz, A. P.,Wendt, C., Zhong, X., State of the art in preservation of fluid biospecimens. Biopreserv. Biobank. 2011, 9, 237-244.
11. Schoonenboom, N. S., Mulder, C., Vanderstichele, H., Van Elk, E.-J. et al., Effects of processing and storage conditions on amyloid β (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 2005, 51, 189-195.
12. Teunissen, C., Petzold, A., Bennett, J., Berven, F. et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73, 1914- 1922.
13. Berven, F. S., Kroksveen, A. C., Berle, M., Rajalahti, T. et al., Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin. Appl. 2007, 1, 699-711.
14. Kroksveen, A., Opsahl, J., Aye, T., Ulvik, R., Berven, F., Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74, 371-388.
15. Plebani, M., Errors in clinical laboratories or errors in laboratory medicine? Clin. Chem. Lab. Med. 2006, 44, 750-759.
16. Del Boccio, P., Pieragostino, D., Lugaresi, A., Di Ioia, M. et al., Cleavage of cystatin C is not associated with multiple sclerosis. Annal. Neurol. 2007, 62, 201-204.
17. Bjerke, M., Portelius, E., Minthon, L., Wallin, A. et al., Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int. J. Alzheimer's Dis. 2010, 2011, 1-11.
18. You, J. S., Gelfanova, V., Knierman, M. D., Witzmann, F. A. et al., The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005, 5, 290-296.
19. Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N. et al., Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's Dement. 2012, 8, 65-73.
20. Kaiser, E., Schönknecht, P., Thomann, P. A., Hunt, A., Schröder, J., Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci. Lett. 2007, 417, 193-195.
21. Rosenling, T., Slim, C. L., Christin, C., Coulier, L. et al., The effect of preanalytical factors on stability of the proteome and selectedmetabolites in cerebrospinal fluid (CSF). J. Proteome Res. 2009, 8, 5511-5522.
22. Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J. M. et al., Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimer's Dis. 2011, 25, 739-745.
23. Perret-Liaudet, A., Dorey, A., Tholance, Y., Dumont, B., Quadrio, I., Pre-analytical and analytical critical factors influencing the high variability of the concentrations levels of Alzheimer disease biomarkers in cerebral spinal fluid. 2013, http://dx.doi.org/10.5772/55512.
24. Blennow, K., Fredman, P., Wallin, A., Gottfries, C.-G. et al., Protein analysis in cerebrospinal fluid. III: relation to bloodcerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. Eur.Neurol. 1993, 33, 134-142.
25. Peskind, E., Nordberg, A., Darreh-Shori, T., Soininen, H., Safety of lumbar puncture procedures in patients with Alzheimers disease. Curr. Alzheimer Res. 2009, 6, 290-292.
26. Petzold, A., CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol. Res. 2007, 29, 691-708.
27. Sastre,M., Calero,M., Pawlik,M., Mathews, P. M. et al., Binding of cystatin C to Alzheimer's amyloid β inhibits in vitro amyloid fibril formation. Neurobiol. Aging 2004, 25, 1033- 1043.
28. Mi, W., Pawlik, M., Sastre, M., Jung, S. S. et al., Cystatin C inhibits amyloid-β deposition in Alzheimer's disease mouse models. Nat. Genet. 2007, 39, 1440-1442.
29. Levy, E., Sastre, M., Kumar, A., Gallo, G. et al., Codeposition of Cystatin C with amyloid-[beta] protein in the brain of Alzheimer disease patients. J. Neuropathol. Exp. Neurol. 2001, 60, 94-104.
30. Chuo, L.-J., Sheu,W. H., Pai, M.-C., Kuo, Y.-M., Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement. Geriatr. Cogn. Disord. 2007, 23, 251-257.
31. Sundelöf, J., Ärnlöv, J., Ingelsson, E., Sundström, J. et al., Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 2008, 71, 1072-1079.
32. Simonsen, A., McGuire, J., Podust, V., Hagnelius, N.-O. et al., A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 2007, 24, 434-440.
33. Perrin, R. J., Craig-Schapiro, R., Malone, J. P., Shah, A. R. et al., Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011, 6, e16032.
34. Jimenez, C. R., Koel-Simmelink, M., Pham, T. V., van der Voort, L., Teunissen, C. E., Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics -Clin. Appl. 2007, 1, 1385-1392.
35. Irani, D. N., Anderson, C., Gundry, R., Cotter, R. et al., Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Annal. Neurol. 2006, 59, 237-247.
36. Larsen, P. D., DeLallo, L. J., Cerebrospinal fluid transthyretin in multiple sclerosis. Neurology 1987, 37, 1262-1262.
37. Pieragostino, D., Del Boccio, P., Di Ioia, M., Pieroni, L. et al., Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis. Proteomics 2013, 13, 1002-1009.
38. del Campo, M.,Mollenhauer, B., Bertolotto, A., Engelborghs, S. et al., Recommendations to standardize preanalytical confounding factors inAlzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers 2012, 6, 419-430.
39. Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R. et al., Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides. Clin. Chem. 2006, 52, 332-334.
40. Choi, Y. S., Hou, S., Choe, L. H., Lee, K. H., Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. J. Chromatogr. B 2013, 930, 129-135.
41. Pan, S., Aebersold, R., Chen, R., Rush, J. et al., Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 2008, 8, 787-797.
42. Legrain, P., Aebersold, R., Archakov, A., Bairoch, A. et al., The human proteome project: current state and future direction. Mol. Cell. Proteomics 2011, 10, M111. 009993.
43. Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P. et al., Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat. Methods 2013, 11, 149-155.